U.S. Capital Markets Stock News

NasdaqGS:CRWV
NasdaqGS:CRWVIT

US Stock Market Today S&P 500 Futures Edge Lower As Inflation And Fed Risks Loom

The Morning Bull - US Market Morning Update Tuesday, Jan, 13 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.1%, as investors focus on three pressure points. First, December consumer price data is expected to show headline and core inflation at 2.7% year on year, a reading that will influence how quickly the cost of living is seen to be easing. Second, the 10 year US government bond yield is around 4.2%, reflecting higher borrowing costs for...
NYSE:UP
NYSE:UPAirlines

A Look At Wheels Up Experience (UP) Valuation After Delta Partnership Expansion And Cost Cutting Plans

Wheels Up Experience (UP) is back in focus after receiving a NYSE notice about its sub US$1 share price, outlining cost reduction plans and expanding its Delta Air Lines partnership to let members book Delta flights through its portal. See our latest analysis for Wheels Up Experience. The NYSE notice and the expanded Delta partnership come after a sharp rebound in the 1 day share price return of 46.58% and a 7 day share price return of 44.45%. However, the 1 year total shareholder return...
NasdaqGM:XNCR
NasdaqGM:XNCRBiotechs

What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders

Xencor recently outlined its 2026 priorities and advancement milestones for its clinical-stage XmAb drug portfolio, highlighting progress across oncology and autoimmune programs, including early anti-tumor activity and tolerability for its lead T-cell engagers. An important takeaway for investors is Xencor’s expectation that its current cash resources should fund research and operations through 2028, supporting multiple planned pivotal studies without near-term financing guidance. We’ll now...
NYSE:BLD
NYSE:BLDConsumer Durables

TopBuild’s (BLD) Dual-Revenue Model: Efficiency Edge or Hidden Concentration Risk Amid Construction Strength?

In recent months, TopBuild has benefited from a construction surge, with its installer-distributor model capturing value from both material markups and installation services, helping it consistently exceed earnings estimates. This dual-revenue approach has allowed TopBuild to enhance margins while some manufacturers face cost pressure, highlighting how its business model can extract more value from robust building activity. We'll now examine how TopBuild's installer-distributor model,...
NasdaqGS:RIGL
NasdaqGS:RIGLBiotechs

Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed?

In January 2026, Rigel Pharmaceuticals issued full-year 2026 earnings guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and US$20 million to US$25 million in contract revenue. This fresh guidance gives investors a clearer view of how management currently sees the balance between core product sales and partnership-driven contract income. We’ll now consider how Rigel’s new 2026 revenue guidance,...